T here are 600,000 bacterial bloodstream infections (BSIs) annually in the United States, more than 75,000 of which result in death. 1 BSIs are particularly lethal when acquired in the intensive care unit (ICU), with a case mortality rate greater than 40%, a 15%-20% absolute increase above baseline ICU mortality. 2 Established risk factors for BSI in the ICU include increased age, multiple comorbidities, and immunosuppression. 3 Potentially modifiable risk factors include indwelling venous or urinary catheters, 4 hygiene and other local environmental factors, 5, 6 and receipt of antibiotics and other medications. 7 Comprehensive strategies to decrease the incidence of ICU-acquired BSI have been effective, 8 although incidence and mortality from BSIs in the ICU remain high.
Proton pump inhibitors (PPIs) are frequently used for prophylaxis against upper gastrointestinal (GI) bleeding in the ICU and are highly effective for this purpose. 10 Current guidelines recommend use of PPIs for stress ulcer prophylaxis in ICU patients with characteristics that place them at high risk for bleeding such as sepsis, extended mechanical ventilation, or coagulopathy. 11 Because most ICU patients have these high-risk characteristics, use of PPIs in the critical care setting is very common. As long as PPIs cause few adverse effects, widespread use of PPIs in the ICU is likely to be of net benefit. 12 There is reason for concern that PPIs may be associated with increased risk for infection and that this association may be particularly strong in critically ill patients. Most notably, PPIs have been associated with increased risk for BSIs and for other infections in cirrhotic patients. 13, 14 Like cirrhotic patients, critically ill patients have crucial risk factors for BSI that may be affected by PPIs including increased intestinal permeability 15 and loss of normal diversity in the GI microbiome. 16, 17 Data investigating the relationship between PPIs and risk for BSI are limited. To evaluate this relationship further, we performed a retrospective cohort study among patients hospitalized in the ICU.
Methods
The institutional review board of Columbia University approved this study.
Data Sources
Data were extracted from the hospital electronic medical record by using algorithms validated for the assessment of healthcare-associated infections and that have previously been described. 18 In brief, diverse sources of electronic data were combined into a single, curated repository that included patient demographics, comorbidities (computed as the Charlson comorbidity index [CCI]), 19 provider order entry data, microbiology results, and insurance claims data. This repository was then queried for relevant outcome and exposure-related data.
Study Population
Adult patients (18 years) were eligible for the study if they were admitted to any 1 of 14 distinct ICUs within a hospital network composed of 3 large hospitals between 2008 and 2014. Patients were excluded if they had an ICU length of stay less than 2 days, if they were diagnosed with BSI before day 3 of their ICU stay (to distinguish prevalent from incident BSI), or if they had GI bleeding during the index hospitalization (identified by appropriate International Classification of Diseases, Ninth Revision [ICD-9] codes). GI bleeding is the main indication for use of PPIs other than stress ulcer prophylaxis, and we wanted to focus the study on use of PPIs for bleeding prophylaxis rather than for management of bleeding. For those with multiple ICU admissions during the study period, only data from the first admission were analyzed.
Bloodstream Infections
BSI was classified as present if a blood culture drawn either peripherally or centrally showed bacterial growth on or after the third ICU day. Otherwise, BSI was classified as absent. This criterion aligns with guidelines from the Centers for Disease Control and Prevention, which define healthcare-associated infections as those arising a minimum of 48 hours after hospitalization. 20 BSI onset was considered to be the time that the positive blood culture was collected. To focus on the possible mechanisms linking PPIs and BSI, we subclassified BSIs as derived from predominantly enteric bacteria (Bacteroides, Enterococcus, Fusobacterium, and the Enterobacteriaceae family of gram-negatives including common pathogens Citrobacter, Enterobacter, Escherichia coli, Klebsiella, Proteus, Salmonella, and Serratia) or derived from predominantly non-enteric bacteria (eg, Staphylococcus aureus).
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Primary Exposure
The primary exposure was receipt of PPIs at any dose or duration, either oral or intravenous, at any time during the follow-up period in the ICU and was classified as present or absent. Exposure to PPIs was extracted through the electronic medical record from nursing flowsheets (ie, based on when PPIs were actually administered) and was classified as present only if PPIs were received at least 1 day before the last day of follow-up.
Covariates
The following variables were extracted: age, sex, race, residence in a long-term care facility before hospital admission, history of solid organ transplant, and baseline comorbidities (CCI). 19 In addition, data were extracted related to ICU exposures: use of hemodialysis, use of gastrostomy tube, mechanical ventilation, major surgery, presence of a central venous catheter or urinary catheter, receipt of histamine-2 receptor antagonists (H2RAs), and receipt of antibiotics in the ICU. Receipt of H2RAs and antibiotics was classified as present if these drugs were given at any dose or duration a minimum of 1 day before the last day of follow-up. Antibiotics were further subclassified as narrow-spectrum or broad-spectrum on the basis of their anticipated impact on the GI microbiome (Supplementary Table 1) . 22 In situations where the spectrum of the antibiotic class was controversial, 23 it was categorized as narrow-spectrum if that class lacked significant activity against anaerobes (eg, monobactam antibiotics). CCI was dichotomized as a score of 2 or less, considered mild, versus 3 or greater, considered moderate to severe. 24 
Statistical Analysis
Descriptive statistics were visualized to determine appropriate cutoffs, and c 2 tests were used to compare categorical variables. The final multivariable analysis was performed by using a Cox proportional hazards model, with patients followed from the time of ICU admission until death, ICU discharge, or for 28 total days (ie, from day 2 until day 30 after ICU admission). The proportionality assumption was verified on the basis of visual inspection and by testing for a non-zero slope in the Schoenfield residuals. We decided a priori that the following variables represented important potential confounders for the PPI-BSI relationship and would be forced into the final model: age, presence of a central venous catheter in the ICU, exposure to antibiotics, and baseline comorbidities. Additional variables were tested stepwise in the model and included if they were independently associated with BSI or if they changed the b-coefficient representing PPIs by 10%. Statistical analyses were performed by using STATA (Stata Corporation, College Station, TX) version 14.1, and statistical significance was defined as P value <.05.
Sensitivity Analyses
To assess the possibility of death as a competing risk for BSI, we performed a stratified analysis that was based on death. We assessed for a dose-response relationship between PPIs and BSIs and also assessed PPIs as a time-varying exposure (ie, patients were coded as unexposed until the day that they received a PPI and as exposed thereafter). To evaluate whether the PPI-BSI relationship depended on the presence or absence of antibiotics, we tested for interactions between PPIs and narrow-spectrum and broad-spectrum antibiotics. Last, because the hypothesized mechanism linking PPIs and BSI involves the translocation of gut bacteria across the intestinal wall, we tested whether exposure to PPIs was a risk factor for infections derived from predominantly enteric bacteria.
Because concerns have been raised regarding PPIs and risk for ventilator-associated pneumonia (VAP), we also extracted data related to the presence or absence of VAPs within this cohort. VAP was classified as present in mechanically ventilated patients who had moderate to heavy bacterial growth from sputum cultures or fluid taken during bronchoalveolar lavage. Because VAP is frequently culture-negative, ventilated patients were also classified as having VAPs if they were coded with ICD-9 or ICD-10 codes for pneumonia. When ventilated patients had neither positive cultures nor appropriate ICD codes, VAP was classified as absent. Because ICD codes did not identify the date on which VAP occurred, logistic regression modeling rather than a Cox model was used to test for an association between PPIs and VAP after adjusting for potential confounders.
Results
Study Population
From 60,764 patients initially evaluated for the study, 24,774 patients met eligibility criteria and were included in the analysis. A total of 756 patients (3.1%) developed BSI between days 3 and 30 of ICU stay. The mortality rate during the index ICU admission was 19% among patients who developed BSIs compared with 7.7% among patients who did not develop BSIs (P < .01). The incidence rate of BSIs was similar throughout the 7 years of the study (P for trend ¼ .26).
Characteristics at Baseline and During Treatment in the Intensive Care Unit
Patients who received prophylaxis with PPIs were older, more likely to be male, and more likely to have received a solid organ transplant and had increased baseline comorbidities compared with patients who did not receive PPIs (Table 1) . During treatment in the ICU, patients who received PPIs were more likely to receive antibiotics and other interventions compared with patients who did not receive PPIs (Table 2) .
Multivariable Model
The cumulative proportion of BSIs was 3.7% in patients exposed to PPIs versus 2.2% in patients who were not exposed to PPIs (log-rank test, P < .01; Figure 1 ). However, after adjusting for potential confounders, there was no association between PPIs and BSIs (adjusted hazard ratio [aHR], 1.08; 95% confidence interval [CI], 0.91-1.29; Table 3 ). When tested in the final model, exposure to H2RAs in the ICU was also not significantly associated with BSI (aHR, 1.01; 95% CI, 0.74-1.38). Increased comorbidities, use of mechanical ventilation, and receipt of narrow-and broad-spectrum antibiotics were independently associated with BSI in the ICU. Within antibiotics, a stronger association with BSI was observed with broad-spectrum antibiotics (aHR, 2.44; 95% CI, 2.00-2.96) compared with narrow-spectrum antibiotics (aHR, 1.70; 95% CI, 1.36-2.13).
Sensitivity Analyses
The relationship between PPIs and BSI remained unchanged when we performed a restriction analysis of 22,776 patients who survived until ICU discharge or the development of BSI (aHR, 1.04; 95% CI, 0.86-1.27).
Results of a Fine-Gray analysis were similar (aHR, 1.11; 95% CI, 0.93-1.34). There was also no difference when we focused on the sickest patients by excluding 9738 patients with less than 2 serious medical comorbidities at the time of ICU admission (aHR, 0.96; 95% CI, 0.79-1.18). Among patients who received at least a single dose of a PPI, 88% received PPIs for more than 50% of ICU days. When patients who received PPIs for <50% of ICU days were excluded, there was no association between PPIs and BSI (aHR, 1.13; 95% CI, 0.94-1.35). When PPIs were examined as a time-varying exposure, there was no association with BSI (aHR, 1.16; 95% CI, 0.97-1.39). There was no interaction between PPIs and either broad-spectrum antibiotics (P ¼ .92) or narrowspectrum antibiotics (P ¼ .39). There was also no significant association between PPIs and BSI when we analyzed only 203 BSIs that were derived from predominantly enteric bacteria (aHR, 1.35; 95% CI, 0.94-1.95). Finally, there was no association between PPIs and VAP (adjusted odds ratio, 1.16; 95% CI, 0.97-1.39; Supplementary Table 2) or PPIs and all-cause mortality (aHR, 1.01; 95% CI, 0.92-1.10).
Discussion
Use of PPIs for stress ulcer prophylaxis in the ICU was not associated with increased risk for BSI, and this null finding was robust through multiple sensitivity analyses.
If the relationship between PPIs and BSI was mediated by PPI-induced changes in intestinal permeability, one might expect that PPIs would increase risk for BSI from enteric but not from non-enteric bacteria. However, there was also no association between PPIs and risk for BSI with predominantly enteric organisms. Comorbidities, antibiotics, and mechanical ventilation were the chief factors influencing risk for ICU-onset BSI. In addition, PPIs were not associated with VAP or with overall ICU mortality.
This study examines the relationship between PPIs and risk for BSIs. Prior studies related to PPIs and risk for systemic infections have focused on cirrhotic patients and risk for spontaneous bacterial peritonitis (SBP). In a meta-analysis by Xu et al, 14 PPI use was associated with 2-fold increased risk for both SBP and overall bacterial infections. In hospitalized cirrhotic patients, long-term PPI use was an independent predictor of subsequent SBP and all-cause infections. 13 Alterations in the GI mucosal barrier and in the GI microbiome in cirrhotic patients are thought to underlie this increased risk. 25 Critically ill patients have similar underlying risk factors for infections. Animal and human studies have shown higher intestinal permeability with slower rates of mucosal healing in the critically ill, leading to increased risk for bacterial translocation and infection. 15, 26 Because most of the data connecting PPIs and extraintestinal infections are derived from cirrhotic patients, the differences between this study and prior studies may indicate that ICU patients have relatively preserved intestinal permeability compared with cirrhotic patients and that BSI in ICU patients usually arises through alternate pathways. There were too few cirrhotic patients in this study to test whether cirrhosis modified the PPI-BSI relationship. Direct evidence that PPIs alter intestinal barrier function is contradictory. In animal models and in humans, PPIs appear to exacerbate small bowel injury that is due to nonsteroidal anti-inflammatory drugs. 27, 28 On the other hand, Jones et al 29 performed gastroduodenoscopy with biopsy on healthy dogs with or without PPIs and found that bacteremia after endoscopy was rare and did not depend on PPI exposure. Luminal microorganisms contribute toward mucosal integrity through diverse mechanisms. 30 Because PPIs appear to alter the human GI microbiome, [31] [32] [33] it has been hypothesized that they may have a detrimental effect on mucosal barrier function that is mediated by the gut microbiota. PPIs have also been found to lead to increases in pathogenic taxa as well as genes involved in bacterial invasion. 31, 34 This study indirectly addressed the question of PPIs and gut barrier function in the ICU. Along with previous studies, these data suggest that PPIs do not meaningfully alter clinical outcomes with respect to some of the most important ICU infections: BSIs, VAP, or Clostridium difficile infection. 35 In the ICU setting, any effects of PPIs may simply be too subtle or too shortlived to exert a downstream effect on risk for BSI or other infections.
Receipt of both narrow-and broad-spectrum antibiotics in the ICU was associated with increased risk for BSI, with a stronger association observed for broad-than narrow-spectrum antibiotics. Previous studies have found that prior antibiotic exposure (within the past 90 days) leads to increased in-hospital mortality from gram-negative bacterial infection. 7 Prior use of broadspectrum antibiotics has been associated with increased risk for ICU-acquired infection. 36 Our findings are consistent with these previous studies and emphasize the potential for antibiotics to impact long-term risk for infections by altering the GI microbiome, immune function, bacterial antibiotic resistance, or other mechanisms. 37 There are limitations to the current study. This was a large study, but we cannot completely exclude the possibility that use of PPIs for stress ulcer prophylaxis is associated with a modest increase in risk for BSI. With regard to the study outcome, only culture-proven BSIs were included in our analysis. Assessment of infection without culture results in the ICU can be subjective, and the requirement for positive culture results may thus minimize the possibility of bias. We were unable to retrospectively assess the indication for PPIs. However, the primary indications for PPI use in the ICU are for stress ulcer prophylaxis and for GI bleeding, and patients with bleeding were excluded from the study. We did not have data on immunosuppressant use, which may impact individual patients' susceptibility to infection. Our study did take into account organ transplant recipients, the majority of whom are on immunosuppressive agents, and this did not impact the relationship between PPIs and ICU-onset BSI. Finally, to focus on incident rather than prevalent BSI, we excluded patients who died within 48 hours of ICU admission. As a result, our cohort may have been healthier than other ICU-based cohorts. 38 In sum, use of PPIs for stress ulcer prophylaxis was not a significant predictor of BSI or VAP in this large, ICU-based cohort. There was no association between PPIs and BSI due to predominantly enteric bacteria and also no PPI-BSI relationship in subjects who received PPIs for a majority of their ICU days. Exposure to both narrow-and broad-spectrum antibiotics was associated with increased risk of ICU-onset BSI, with a stronger association observed for broad-spectrum antibiotics; the potential for antibiotics to increase risk for BSI and other infections merits further study. Our null findings regarding PPIs provide important reassurance that concern for BSIs should not drive the decision regarding whether to use PPIs for stress ulcer prophylaxis in the ICU. More generally, our findings do not support the hypothesis that PPIs significantly alter intestinal permeability to predispose to BSIs or other infections.
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